Centaurus Financial - we invest in your success
CuraDebit Free Debt Analysis
  Home > Fortune 500 Companies > Schering Plough

Schering-Plough




Schering-Plough is a fortune 500 stock listed company trading under the symbol SGP.The Company has a good stock performance record. Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs.
 
Schering-Plough reported full-year 2005 GAAP net sales were 9.5 billion dollars which is up 15 percent versus 2004. Contributing 4 percent to the sales increase were sales for AVELOX, CIPRO and other products under the Bayer agreement, which became effective in October 2004. Including an adjustment of an assumed 50 percent of global cholesterol joint venture net sales, Schering-Plough's adjusted net sales for 2005 would have totaled 10.7 billion dollars an increase of 1.8 billion dollars or 21 percent, as compared to 8.9 billion dollars on a similar adjusted basis in 2004. The higher sales on an adjusted basis were largely due to the strong growth of the cholesterol franchise combined with solid performance in six of the company's top 10 prescription products, where double-digit sales growth was recorded versus 2004.
 
Schering-Plough reported net income available to common shareholders of 104 million dollars in the 2005 fourth quarter or 7 cents per common share compared with a net loss available to common shareholders in the 2004 period of 856 million dollars or 58 cents per share. The net loss available to common shareholders and loss per share in the 2004 fourth quarter reflected a tax provision of 807 million dollars or 55 cents per share, relating primarily to the American Jobs Creation Act of 2004.
 
The fourth quarter 2005 GAAP net sales of 2.3 billion dollars were 6 percent higher than the 2004 period. The sales increase was driven by the growth of prescription pharmaceuticals, led by PEG-INTRON, REBETOL, NASONEX and REMICADE. The sales growth versus 2004 includes a 3 percent unfavorable impact from foreign exchange. Fourth quarter 2005 GAAP net sales of Prescription Pharmaceuticals, which do not include sales of the cholesterol joint venture, totaled 1.9 billion dollars which is up 10 percent, including an unfavorable impact from foreign exchange of 3 percent. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 30,000 people around the world.

The Company seeks to achieve superior customer satisfaction through innovative products, comprehensive health and related benefits choices, effective service and easy-to-understand information.

Back to Fortune 500 Companies

 
 
Infinit-i